» Articles » PMID: 30371285

Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction

Overview
Date 2018 Oct 30
PMID 30371285
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Background The Meta-Analysis Global Group in Chronic Heart Failure ( MAGGIC ) mortality risk score, derived from a large sample of patients with heart failure ( HF ) across the spectrum of ejection fraction ( EF ), has not yet been externally validated in a well-characterized HF with preserved EF cohort with adjudicated morbidity outcomes. Methods and Results We evaluated the MAGGIC risk score (composed of 13 clinical variables) in 407 patients with HF with preserved EF enrolled in a prospective registry and used Cox regression to evaluate its association with morbidity/mortality. We used receiver-operating characteristic analysis to compare the predictive ability of the MAGGIC risk score with the more complex Seattle Heart Failure Model, and we determined the value of adding B-type natriuretic peptide to the MAGGIC risk score for risk prediction. During a mean follow-up time of 3.6±1.8 years, 28% died, 32% were hospitalized for HF , and 55% had a cardiovascular hospitalization and/or death. The MAGGIC score, a mean± SD of 18±7, was significantly associated with mortality ( P<0.0001), HF hospitalizations ( P<0.0001), and the combined end point of cardiovascular-related hospitalizations or death (hazard ratio, 1.8 [95% confidence interval, 1.6-2.1], per 1- SD increase in the MAGGIC score; P<0.0001). Receiver-operating characteristic analyses showed that MAGGIC and Seattle Heart Failure Model performed similarly in predicting HF with preserved EF outcomes, but the MAGGIC score demonstrated better calibration for hospitalization outcomes. Further analyses showed that B-type natriuretic peptide was additive to the MAGGIC risk score for predicting outcomes ( P<0.01 by likelihood ratio test). Conclusions The MAGGIC risk score is a simple, yet powerful method of risk stratification for both morbidity and mortality in HF with preserved EF . Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT01030991.

Citing Articles

Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF.

McDowell K, Docherty K, Campbell R, Henderson A, Jhund P, Claggett B JAMA Cardiol. 2025; .

PMID: 40042880 PMC: 11883611. DOI: 10.1001/jamacardio.2025.0025.


Predicting 28-day all-cause mortality in patients admitted to intensive care units with pre-existing chronic heart failure using the stress hyperglycemia ratio: a machine learning-driven retrospective cohort analysis.

Li X, Yang X, Dong B, Liu Q Cardiovasc Diabetol. 2025; 24(1):10.

PMID: 39780223 PMC: 11714879. DOI: 10.1186/s12933-025-02577-z.


Comparison of Physical Frailty Assessments in Heart Failure With Preserved Ejection Fraction.

Zainul O, Marshall D, Lau J, Kelly B, Zarzuela K, Damluji A JACC Adv. 2024; 3(12):101395.

PMID: 39736919 PMC: 11683403. DOI: 10.1016/j.jacadv.2024.101395.


Prognostic effects of glycaemic variability on diastolic heart failure and type 2 diabetes mellitus: insights and 1-year mortality machine learning prediction model.

Yang Z, Li Y, Liu Y, Zhong Z, Ditchfield C, Guo T Diabetol Metab Syndr. 2024; 16(1):280.

PMID: 39578908 PMC: 11585110. DOI: 10.1186/s13098-024-01534-2.


Predicting 30-Day and 1-Year Mortality in Heart Failure with Preserved Ejection Fraction (HFpEF).

Shin I, Bhatt N, Alashi A, Kandala K, Murugiah K medRxiv. 2024; .

PMID: 39484276 PMC: 11527066. DOI: 10.1101/2024.10.15.24315524.


References
1.
Aaronson K, Schwartz J, Chen T, Wong K, Goin J, Mancini D . Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997; 95(12):2660-7. DOI: 10.1161/01.cir.95.12.2660. View

2.
Sartipy U, Dahlstrom U, Edner M, Lund L . Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish heart failure registry. Eur J Heart Fail. 2014; 16(2):173-9. DOI: 10.1111/ejhf.32. View

3.
Shah S, Katz D, Deo R . Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Fail Clin. 2014; 10(3):407-18. PMC: 4076705. DOI: 10.1016/j.hfc.2014.04.008. View

4.
Komajda M, Carson P, Hetzel S, McKelvie R, McMurray J, Ptaszynska A . Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2010; 4(1):27-35. DOI: 10.1161/CIRCHEARTFAILURE.109.932996. View

5.
Burke M, Katz D, Beussink L, Selvaraj S, Gupta D, Fox J . Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2013; 7(2):288-99. PMC: 5947992. DOI: 10.1161/CIRCHEARTFAILURE.113.000854. View